CD38 and neoplasm: In contrast, the combination of anti-CD38 antibody, L82-pulsed DC vaccine, and CpG suppressed LLC1 tumor growth (p = 0.019), although neither anti-CD38 mAb nor L82-pulsed DC monotherapy alone could do so (Figure 7A).